



Be part of research

Research opportunities for children and young people with JIA*

*Juvenile idiopathic arthritis

This leaflet contains information on research studies taking place across the United Kingdom (UK) which children and young people with JIA can take part in.

Only brief summaries are provided, and not all inclusion and exclusion criteria are listed. If you or your child are interested in taking part in any of the research studies, please speak to your rheumatology team!

This document can be downloaded from: www.liverpool.ac.uk/eatc-for-

children/research/workstreams/jia

Last updated: September 2020

This leaflet has been developed, and is regularly updated by members of the NIHR Clinical Research Network: Children/Versus Arthritis Paediatric Rheumatology Clinical Studies Group.



If you are interested in a research study (even if it isn't at your usual hospital), mention it to your rheumatology team!

Observational research studies

Observational research studies are where researchers look at groups of people with similar health conditions or treatments and collect information about them and their condition(s).

Some studies have an acronym (e.g. BCRD). For each study, there is a short description, a website link and email address (if there is one) and the name of the researcher looking after the study.

BCRD REGISTER

	Professor Kimme Hyrich
https://sites.manchester.ac.uk/bcrdbspar/	

BSPAR ETN

	Professor Kimme Hyrich
--	---------------------------

CHARMS

	Professor Lucy Wedderburn
www.sparkscharms.org.uk	

CLUSTER

A collaborative project bringing together data from many JIA and JIA uveitis studies to design ways to predict treatment response and disease outcomes.	Professor Lucy Wedderburn
www.clusterconsortium.org.uk	
Fatjon Dekaj, CLUSTER Research Coordinator: f.dekaj@ucl.ac.uk	

If you are interested in a research study (even if it isn't at your usual hospital), mention it to your rheumatology team!

Interventional research studies

Interventional research studies are where people are assigned to groups that receive one or more interventions or treatments (e.g. a medicine, an exercise, an online resource), or no intervention at all. Researchers then look at the effect of the intervention or treatment on health and wellbeing.

Some studies have an acronym (e.g. ADJUST). For each study, there is a short description, the locations where the study is taking place, a website link and email address (if there is one), and the name of the researcher(s) looking after the study.

ADJUST

ADJUST stands for 'Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial'. Children and young people (2 years and older) with a diagnosis of juvenile idiopathic arthritis-associated uveitis who are currently taking adalimumab (Humira®) or adalimumab biosimilars and are interested in stopping their medication may be eligible for this 12-month study.

Professor Athimalaipet Ramanan

Open hospital locations: Bristol

Soon to open hospital locations: Liverpool, London (GOSH),

Newcastle, Sheffield, Southampton

www.clinicaltrials.gov/ct2/show/NCT03816397

ADJUST@ucsf.edu

Empalumab in MAS

A study looking at how well a new biological medicine called emapalumab works in children and young people with macrophage activation syndrome (MAS), which may develop on the background of systemic JIA.

Professor Paul Brogan

Dr. Despina Eleftheriou

Open hospital locations: London (GOSH)

www.clinicaltrials.gov/ct2/show/NCT03311854

Interventional research studies

*Baricitinib is available as a tablet and liquid (suspension)!

Baricitinib* in polyarticular JIA

A study looking at how well baricitinib, an oral Janus Kinase (JAK) inhibitor medicine, works for children and young people with polyarticular JIA.

Professor Athimalaipet Ramanan

Open hospital locations: Bristol, Liverpool, London (GOSH/UCLH), Sheffield

www.clinicaltrials.gov/ct2/show/NCT03773965

Baricitinib* in systemic JIA

A study looking at how well baricitinib, an oral Janus Kinase (JAK) inhibitor medicine, works for children and young people with systemic JIA.

Professor Athimalaipet Ramanan

Open hospital locations: Bristol, Liverpool, London (GOSH), Sheffield

www.clinicaltrials.gov/ct2/show/study/NCT04088396

Baricitinib* in JIA-associated uveitis and chronic anterior uveitis

A study looking at how well baricitinib, an oral Janus Kinase (JAK) inhibitor medicine, works for children and young people with JIA-associated uveitis and chronic anterior uveitis.

Professor Athimalaipet Ramanan

Open hospital locations: Bristol, Cambridge, Liverpool, London (GOSH), Newcastle, Sheffield, Southampton

www.clinicaltrials.gov/ct2/show/NCT04088409

If you are interested in a particular study but it isn't taking place at your usual hospital, ask your rheumatology team to contact the research team looking after the study. You can show this summary to your rheumatology team if they want more information.